OUR VISION
The Future of Cell Therapy, Beyond the Speed of Disease, Scaled to Treat Every Patient
A World In Need of Cures
Cell therapies have the potential to cure millions of patients battling complex diseases. However, persistent reliance on outdated manufacturing processes reinforces critical barriers to production, deepening the gap in access, cost, and patient demand. As a result, critically ill patients often face prolonged waiting periods for treatment, with up to 25% tragically passing away before receiving life-saving care. Furthermore, the average cost of cell therapy often exceeds $500,000 per patient, making CAR-T therapy one of the most expensive drugs covered by Medicare. Without transformative advancements, production inefficiencies could leave up to 2 million eligible patients without access to life-changing therapies by 2030.
Harton is closing this gap.
About Harton
Harton is transforming the future of cell therapy manufacturing with our innovative GMP-ready, Solid-State Bioprocessing Platform. This groundbreaking solution streamlines complex workflows, enabling efficient production at every stage—from therapeutic development to clinical trial doses—ultimately treating every eligible patient.
As the first platform to achieve full stack automation, Harton sets the industry standard for precision, control, and scalability, delivering consistent, high-quality therapies. By overcoming critical manufacturing barriers, we empower the industry to meet the soaring demand for curative treatments and expand patient access globally.
We’re not just envisioning brighter futures—we’re developing the foundation to make them a reality.
“The future of curing patients relies on more complex and sophisticated treatments. The way we manufacture these therapies must evolve as medicine shifts toward personalized therapies—where each dose is tailored to a single patient. We’re fully committed to transforming cell therapy to meet this challenge.”
Board of Directors
Richard Terry
CEO, CTO, Founder
Evan R. Daugharthy, PhD
President, CSO, Founder
Min Cui, PhD
Founder & Managing Director
Decheng Capital
Victor Tong, Jr.
Managing Director
Decheng Capital
Advisors
George Church, PhD
Professor, Harvard Medical School & MIT
Founding Core Faculty, Wyss Institute at Harvard University
Yvonne Chen, PhD
Professor, Immunology, Microbiology & Molecular Genetics
UCLA
Dennis Flannelly, MBA
Vice President, Precision Medicine CoE
Merck
Laura Brass, PhD, MBA
Managing Director
Novartis Venture Fund